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Abstract: Achieving a cure for high-risk neuroblastoma, the most common extracranial solid 
tumor in children, remains a formidable task despite the recent addition of antibody-mediated 
anti-GD2 immunotherapy to established multimodality therapy. The PI3K/Akt pathway is a 
pivotal signaling pathway utilized by a plethora of receptor tyrosine kinases that contribute to 
the aggressive phenotype of high-risk neuroblastoma. Akt is aberrantly activated in high-risk 
neuroblastoma and is therefore an attractive therapeutic target. Perifosine is the best-characterized 
Akt inhibitor in preclinical studies and in clinical trials in adults, although safety in children is not 
yet confirmed. It is a synthetic third-generation alkylphospholipid with good oral bioavailability 
and modest side effects. Perifosine targets the lipid-binding PH domain of Akt and inhibits the 
translocation of Akt to the cell membrane, an essential step for Akt activation. It decreases Akt 
phosphorylation and increases caspase-dependent apoptosis in neuroblastoma cell lines, inhibits 
growth of neuroblastoma xenografts, and overcomes RTK/ligand-mediated chemoresistance. It 
is currently being studied in two Phase I clinical trials in children with recurrent or refractory 
solid tumors including neuroblastoma. In the single agent trial (ClinicalTrials.gov identifier 
NCT00776867), maximum tolerated dose has not yet been reached and pharmacokinetic data 
has been accrued. In the second study (ClinicalTrials.gov identifier NCT01049841), patients 
are treated with a combination of perifosine and the mTOR-inhibitor temsirolimus based on 
preclinical data showing synergy of the two agents, and the premise that direct Akt inhibition 
may overcome Akt activation secondary to mTOR inhibition. Based on results from adult trials, 
it is unlikely that perifosine alone will produce dramatic therapeutic effects against high-risk 
neuroblastoma. However, given the recent encouraging early-phase combination therapy results 
in adults with multiple myeloma and colorectal carcinoma, rational perifosine-containing com-
bination regimens hold promise for neuroblastoma therapy. These will be explored after safety 
in children is established in Phase I studies.
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Introduction
Curing neuroblastoma, the most frequent pediatric solid tumor outside the central 
nervous system, remains a challenge. Although it accounts for approximately 7% of 
malignancies in patients younger than 15 years, neuroblastoma accounts for 15% of all 
pediatric oncology deaths.1 Neuroblastoma arises from the neural crest cells of the sym-
pathetic nervous system, and exhibits a diverse clinical picture. Infants may experience 
complete regression of the disease without any therapy; and cytotoxic therapy can be 
withheld for most patients with locoregional disease. However, most patients have meta-
static disease at diagnosis, and the prognosis for those diagnosed .18 months of age or 
those with MYCN-amplified disease is poor despite   aggressive multimodality therapy. 
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Tumors initially respond to intensive chemotherapy, surgery, 
and radiotherapy;   however most patients relapse and become 
resistant to   chemotherapy.2 Disialoganglioside (GD2) has 
thus far been the most-frequently targeted tumor antigen on 
neuroblastoma.3 Antibody-based anti-GD2 immunotherapy 
with or without myeloablative therapy and autologous stem 
cell transplant has shown encouraging results with signifi-
cantly improved short-term survival.4,5 However, currently, 
long-term event-free survival for patients diagnosed with 
high-risk disease (which constitute the majority of neuroblas-
toma cases) as reported in multi-center studies is 40%.6–9 
Patients with recurrent neuroblastoma have a far worse out-
come.10 Early tumor detection by screening did not reduce 
  tumor-related mortality.11,12 Therefore, new therapeutic 
strategies are needed to improve the outcome.
Advances in our understanding of the biology of 
  neuroblastoma have given us insights in identifying neu-
roblastoma-specific molecular targets for novel   therapy. 
  Certain genetic alterations are associated with more 
aggressive phenotype and high-risk disease. These include 
MYCN-  amplification, 1p deletion, loss of heterozygosity 
at chromosome 11q, and 17q gain.13 However, correspond-
ing viable targetable molecules for therapy have not been 
  identified. Recently, mutations and amplifications of anaplas-
tic lymphoma kinase (ALK) have been described in small 
subsets of patients of neuroblastoma.14–16 This has led to the 
hope that ALK inhibitors may provide effective therapeutic 
options for patients with neuroblastoma, and early phase 
studies are underway. In addition, high-risk neuroblastoma 
is   associated with elevated expression of the neurotrophin-
receptor tropomyosin receptor kinase TrkB which is 
  considered to act as an oncogenic kinase in a subset of 
patients.17 A safe and biologically effective dose of the multi-
kinase   inhibitor lestaurtinib which has anti-TrkB activity has 
recently been established, though single agent activity against 
neuroblastoma is modest.18,19 TrkB activates the downstream 
phosphatidylinositol 3′-kinase (PI3K)/Akt pathway as do a 
plethora of other receptor tyrosine kinases (RTKs) implicated 
in neuroblastoma pathogenesis and behavior.20,21 Therefore 
Akt inhibition may be therapeutically effective for high-risk 
neuroblastoma. In this review, we focus on the role of the 
Akt pathway in neuroblastoma and specifically, a possible 
therapeutic role for the Akt inhibitor perifosine.
PI3K/Akt signaling pathway
The PI3K/Akt pathway is a key signaling pathway 
that   contributes to cell growth, proliferation, survival, 
  angiogenesis, and glucose metabolism.22–24 Upon growth 
factor binding, transmembrane RTKs are activated by 
  phosphorylation that in turn activates PI3K.25 Activation of 
PI3K generates phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) which then anchors the serine/threonine kinase Akt 
to the plasma membrane via the binding of PIP3 to the 
  pleckstrin homology (PH) domain of Akt.26 The binding 
triggers a conformational change of Akt and releases the 
autoinhibition function of the PH domain. This results in 
the exposure of the two crucial amino acid sites: threonine 
308 (Thr308) in the activation loop of the kinase; and 
  serine 473 (Ser473) at the C-terminus for phosphorylation. 
Activation of Akt requires both translocation to the plasma 
membrane and phosphorylation of the two key residues by 
phosphoinositide-dependent kinase (PDK)-1 and PDK-2.27 
Once activated, Akt   dissociates from the plasma membrane 
and moves to various cellular compartments and targets 
downstream   substrates including mammalian target of 
rapamycin (mTOR) pathway.22,28 A key negative regulator of 
Akt signaling is the tumor suppressor gene phosphatase and 
tensin homolog (PTEN). PTEN can dephosphorylate PIP3 
and thereby inhibit PI3K/Akt signaling.28 This pathway is 
also negatively regulated by protein serine/threonine phos-
phatase which specifically dephosphorylates Ser473.22,29,30 
(Figure 1).
PI3K/Akt pathway and 
neuroblastoma
Aberrant activation of the Akt pathway has been widely 
implicated in many cancers.31 It is one of the most fre-
quently involved pathways in sporadic human tumors, with 
  estimates suggesting that mutation in one or another PI3K/
Akt pathway component accounts for up to 30% of all human 
cancers.23,32 Conversely PTEN is considered to be a major 
tumor suppressor.33 In one study, tissue microarray analysis 
revealed phosphorylation of Akt at Ser473 and Thr308 in 
57% of primary neuroblastoma samples tested. Activation 
was highly correlated with the phosphorylation of S6 ribo-
somal protein, a downstream target of mTOR pathway. Acti-
vation of the Akt pathway correlated with several parameters 
of aggressive disease, including MYCN amplification, chro-
mosome 1p aberrations, advanced disease stage, older age at 
diagnosis, and unfavorable histology.34   Phosphorylation of 
Akt correlated with decreased event-free or overall survival 
of neuroblastoma patients, but S6 or extracellular signal-
regulated kinase (ERK) phosphorylation did not.34 Another 
group studied 39 high-risk neuroblastoma samples using 
phospho-antibodies specifically for the phosphorylated 
proteins in PI3K/AKT pathways. It was found that most of 
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the tumors were positive for PI3Kp85 and PI3Kp110, as 
well as for phosphorylated Akt, mTOR, and S6.35 In another 
study, expression of activated Akt and mTOR was detected 
in all 34 primary neuroblastoma tissue samples tested, but 
not in non-malignant adrenal medullas.36 Lower levels of Akt 
activation were detected in low-risk neuroblastoma (tumors 
expected to mature or regress spontaneously) detected by 
mass screening when compared to classical neuroblastoma.37 
In vitro studies suggest that the PI3K/Akt plays a key role in 
neuroblastoma cell survival   mediated by RTK ligands/RTKs 
including TrkB/brain-derived neurotrophic factor (BDNF),38 
  insulin-like growth factor (IGF)/IGF-receptor,39,40 epidermal 
growth factor (EGF)/EGF-receptor,41,42   platelet-derived 
growth factor (PDGF)/PDGF-receptor,43 and vascular 
endothelial growth factor (VEGF)/VEGF-receptor.44–46 
  Several studies also indicate that Akt is involved in con-
trolling apoptosis in neuroblastoma cells through caspase-
  dependent and   caspase-independent mechanisms,47,48 in 
protein synthesis and cell growth via downstream mTOR 
signaling,49 and in cell cycle control via interaction with 
glycogen synthase kinase-3β (GSK3).50,51 Recently, Akt 
regulation in neuroblastoma cells has been linked to the 
micro RNAs miR-14952 and miR-184.53   Activation of the 
Akt pathway in neuroblastoma can be caused by mutation 
or overexpression of RTKs and/or their ligands. Besides the 
above growth factors/receptors, activating ALK mutations 
have been shown to enhance Akt activity.16,54,55 The Akt path-
way can also be aberrantly activated by inactivation of tumor 
suppressor PTEN by homozygous deletion or promoter 
hypermethylation.56,57 In addition, several other proteins 
can influence Akt activation or inhibition in neuroblastoma. 
These include TNF-related apoptosis inducing ligand 
(TRAIL),58 PKC family proteins,59 and FOXO3a.60 In sum-
mary, based on current studies, Akt is aberrantly activated 
in a majority of high-risk neuroblastic tumors, and appears 
to be an important mediator of the cancer phenotype in 
neuroblastoma. However, unlike in some adult cancers, Akt/
PI3 K mutations have not been detected in neuroblastoma 
including in a high-throughput sequenom-based analysis of 
a large number of primary tumors.61
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Figure 1 Diagrammatic representation of the Akt signaling pathway. 
Notes: Activation of receptor tyrosine kinase (RTK) by growth factor binding activates PiK3. Activated Pi3K phosphorylates PiP2 and generates PiP3, a reaction that can be 
reversed by PTEN. The PH domain of Akt binds to PiP3, which then triggers a conformational change of Akt that results in the phosphorylation of two critical amino acids, 
Thr308 and Ser473 by PDK-1 and TORC2 respectively. The phosphorylated Akt then dissociates from the plasma membrane and targets downstream pathways including 
cell growth, survival, proliferation, and metabolism. Besides PTEN, this pathway is also negatively regulated by PHLPP, a protein serine/threonine phosphatase that can 
dephosphorylate Ser473 of Akt.
Abbreviations: PiP2, Phosphatidylinositol (4,5)-bisphosphate; PiP3, Phosphatidylinositol (3,4,5)-trisphosphate; PDK1, 3-Phosphoinositide-dependent protein kinase 1; TORC2, 
mammalian target of rapamycin complex 2; PTEN, Phosphatase and tensin homolog; PHLPP, PH domain and Leucine rich repeat protein phosphatases; mTOR, mammalian 
target of rapamycin Bad, Bcl-xL/Bcl-2-associated death promoter; FKHR, Forkhead transcription factors; MDM2, mouse double minute 2; GSK3, glycogen synthase kinase 3.
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Targeting the Akt pathway
Recent attention has been focused on the concept of 
  “oncogene addiction,” which hypothesizes that cancer cells 
are dependent on, or “addicted” to, one or a few genes for both 
maintenance and survival of the malignant cells.62   Therefore, 
inhibiting only one or a few of these abnormalities may 
inhibit cancer cell growth and translate to improved outcome. 
Because Akt is at the pivotal nodal point in the signaling 
pathway of a majority of RTKs, and the activation of the Akt 
pathway has been frequently found in cancers, it is an attrac-
tive target for novel anticancer drugs. If Akt is inhibited, the 
survival signaling of most RTKs will be blocked, obviating 
the need to identify tumor-specific “drug-able” genetic/epi-
genetic changes or patient tumor-specific RTKs. Substrates 
downstream of Akt critical for cell survival can be cell type 
specific, and inhibition of individual substrates may miss key 
targets that are responsible for cell survival and proliferation. 
Directly targeting Akt can circumvent feedback activation 
of Akt that has been observed with mTOR inhibition.22,69 
Therefore, direct targeting of Akt, especially in tumors with 
an activated Akt pathway such as neuroblastoma, has the 
potential to be therapeutically effective. Various strategies 
have been used to develop Akt inhibitors, including screen-
ing small molecules that target the ATP-binding domain or 
the PH domain of Akt, and designing peptides that model 
the interaction of Akt with inhibitory binding proteins.63,68,69 
Several Akt inhibitors are in early phase clinical trials for a 
variety of cancers.64 Perifosine is the most well characterized 
and clinically evaluated Akt inhibitor thus far.
Perifosine: an anticancer  
Akt inhibitor
Perifosine is a synthetic oral alkylphospholipid with a 
  piperidine head group. It is a third generation anti-tumor 
  alkylphospholipid analog related to miltefosine and edelfosine, 
but with better oral availability and fewer   gastrointestinal 
side effects.65 The synthetic alkylphospholipids are 
  membrane-permeable ether lipids that are easily inserted into 
the outer leaflet of the plasma membrane and subsequently 
induce profound biological changes and ultimately lead to 
cell death.63,66,68,69 Perifosine targets the lipid-binding PH 
domain of Akt and inhibits the translocation of Akt to the 
cell membrane, an essential step for the activation of Akt.67–70 
Perifosine has also been shown to inhibit MAPK71 and JNK72 
pathways. In vitro, perifosine inhibits Akt at low micromolar 
concentrations and causes apoptosis in many human cancers 
including multiple myeloma, T-acute lymphoblastic leukemia, 
acute myeloid leukemia, non-small cell lung carcinoma, 
prostate carcinoma, hepatocellular carcinoma, ovarian car-
cinoma, and medulloblastoma.72–80 In vivo, Akt inhibition 
by perifosine has been documented in xenograft mouse 
models of multiple myeloma,81–83 glioma,84 Waldenstrom’s 
macroglobulinemia,85 breast, ovarian, and prostate cancer.86 
Cell lines with activating Akt pathways are more sensitive 
to perifosine in vitro than those without, and the ability of 
perifosine to inhibit tumor in vivo is correlated with the 
decreases in phosphorylation of Akt and other components 
of the pathway in the tumor.86 In pediatric tumors other 
than neuroblastoma, perifosine-induced Akt inhibition has 
been demonstrated in a brainstem glioma mouse model,87 
and it was shown to act as a radiation-sensitizer in murine 
medulloblastoma.88
Perifosine has been tested in several clinical trials in adults 
with various tumor types. In Phase I studies, the maximum-
tolerated dose was determined to be 150 mg orally for each 
of the four loading doses on day 1 followed by 100 mg 
orally once daily as maintenance.89 The maximum tolerated 
maintenance daily dose of perifosine was 200 mg/day,90 and 
the half-life was estimated to be about 4 days.91 Perifosine 
was well tolerated in general, with common   toxicities being 
gastrointestinal symptoms and fatigue.   Toxicities were less 
than grade 3 in the majority of patients. Bone marrow sup-
pression was minor.89,90 Multiple adult Phase II trials using 
perifosine in various solid tumor and sarcomas have been 
completed. Single agent anti-tumor activity was modest and 
was noted against sarcoma,92 Waldenstrom’s macroglobuline-
mia,93 renal cell carcinoma, and non-small cell lung cancer.64 
A randomized placebo-controlled Phase II study comparing 
perifosine plus capecitabine to capecitabine alone as second 
or third-line therapy in patients with metastatic colorectal 
carcinoma showed significantly better time to progression and 
overall survival for patients treated with the combination.94 
Similarly, the combination of perifosine plus bortezomib 
and dexamethasone demonstrated encouraging activity in 
pretreated bortezomib-exposed patients with resistant multiple 
myeloma.95 Phase III studies have now been initiated for both 
colorectal cancer and for multiple myeloma.
Perifosine: preclinical studies  
in neuroblastoma
Constitutively activated Akt has been detected in   neuroblastoma 
cell lines and increases cell survival;38 in primary tumors. It 
is associated with high-risk disease.34
Activation of neuroblastoma RTKs can increase Akt 
activation and mediate chemoresistance,   warranting 
  consideration of Akt as a tumor target for therapy. 
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  Perifosine in µM concentrations decreased Akt phospho-
rylation and increased caspase-dependent apoptosis in four 
different neuroblastoma cell lines bearing different genetic 
and   biological characteristics resembling a spectrum of 
high-risk neuroblastoma.96 In xenograft models, perifos-
ine inhibited the growth of neuroblastoma tumors with an 
improved survival of perifosine-treated mice with minimal 
toxicity. Xenografts in perifosine-treated mice showed inhi-
bition of Akt activation and induction of caspase-dependent 
  apoptosis.96 Interestingly, neuroblastoma cell lines with both 
wild-type and mutant ALK were sensitive to perifosine. The 
role of perifosine in overcoming chemoresistance was tested 
in a TrkB-expressing neuroblastoma cell line TB3 which 
demonstrates BDNF-induced Akt activation. Pre-treatment 
with perifosine blocked brain-derived neurotrophic factor 
(BDNF)/TrkB-induced TrkB phosphorylation and attenu-
ated BDNF-mediated etoposide chemoresistance in vitro. In 
mice bearing TB3 xenografts, the combination of perifosine 
and etoposide reduced tumor growth significantly when 
compared to treatment with either drug alone, suggesting a 
role for perifosine in overcoming chemoresistance mediated 
by Akt-activation.97
Rationale for combination 
strategies with perifosine
The results of Phase II trials using perifosine as a single 
agent are modest.64 However, data from perifosine-including 
combination therapies for multiple myeloma and colorectal 
cancer are encouraging.94,95 It is likely that cancers depend 
on more than one pathway for their proliferation and sur-
vival and inhibitors of a single deregulated pathway may be 
insufficient to induce cell death. Indeed in vitro, perifosine 
has been shown to have a synergistic antitumor effect when 
combined with various biological agents including   UCN-01,98 
histone deacetylase inhibitors,99 TRAIL,73,100 erlotinib,75 
cetuximab,71 and 17-DMAG.101 In particular, simultane-
ous targeting of the Akt pathway by perifosine and mTOR 
inhibition induced cell death and decreased proliferation 
in murine glioblastoma studies.102 In addition, perifosine 
synergizes with conventional chemotherapy agents against 
multiple myeloma,82 endometrial cancer,103 and acute myeloid 
leukemia.104 In murine medulloblastoma and brain stem 
glioma model,   perifosine has been shown to sensitize tumor 
cells to radiation therapy.88,105 Taken together, these preclini-
cal data suggest that combination therapy can increase the 
cytotoxic effect of perifosine, and Akt inhibition can sensi-
tize the responsiveness of tumor cells to   chemotherapy and 
radiation therapy. In preclinical studies of TrkB-expressing 
neuroblastoma xenografts, both perifosine and   lestaurtinib106 
synergize with   chemotherapy, suggesting that TrkB-medi-
ated   chemoresistance can be overcome by inhibition of 
  RTK-driven survival pathways. Since perifosine has little 
bone marrow toxicity, combination conventional chemo-
therapy with perifosine could lead to being more   effective 
in tumor killing without major myelosuppression.
Perifosine: clinical studies  
in neuroblastoma
Perifosine is currently being tested in two ongoing 
  pediatric Phase I studies, both being conducted at Memo-
rial   Sloan-Kettering Cancer Center. The first is a Phase I 
dose escalation study of perifosine as a single agent for 
recurrent pediatric solid tumors including neuroblastoma 
(ClinicalTrials.gov identifier number NCT00776867). This 
has a standard Phase I design to determine the maximal 
tolerated dose (MTD) of perifosine in children. Given the 
restrictions of perifosine oral formulation (only available in 
50 mg tablets), the drug is not dosed per surface area, but in 
five groups where grouping is based on body surface area. 
All patients receive an oral load on day 1 (50–300 mg) fol-
lowed by maintenance doses (50–200 mg) ranging from once 
every 4 days to once daily. This corresponds to an initial dose 
level of approximately 25 mg/m2/day with increments of 
25 mg/m2/day per dose level. Perifosine is a potential substrate 
for the cytochrome P450 system which is induced by enzyme 
inducing anti-epileptic drugs; hence, patients are not allowed 
to receive the latter concurrently with perifosine. Dose-lim-
iting toxicities monitored for include any non-hematological 
toxicity $grade 3 and severe myelosuppression. Secondary 
objectives include assessment of perifosine pharmacokinetics 
and correlation of molecular features of tumors with response, 
if any. Preliminary data were reported on nine patients (includ-
ing two patients with neuroblastoma) treated at the first three 
dose levels. No dose-limiting toxicities were reported and 
MTD has not yet been reached. Grade 2 toxicities possibly 
related to perifosine included asthenia (22%), asymptomatic 
hepatic transaminase elevation (22%), neutropenia (33%), 
leukopenia (11%), hyperglycemia (22%), hypomagnesemia 
(22%), hypophosphatemia (11%), and colitis which resolved 
despite drug continuation (11%). Preliminary pharmacoki-
netic data resulted in the following steady state serum levels: 
14.1 ± 4 µM for dose level 1, 32.8 ± 8.1 µM for dose level 2, 
and 31.6 ± 7.8 µM for dose level 3.107 Both patients did not 
show disease progression at 9+ months on therapy.108 Given 
the excellent safety profile observed at the third dose level, 
additional patients with neuroblastoma have been treated 
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at dose level 3 for a preliminary evaluation of efficacy of 
perifosine monotherapy against neuroblastoma. To date, an 
additional twelve patients with neuroblastoma have been 
treated on the protocol.
The second study investigates the combination of 
  perifosine and temsirolimus in a Phase I clinical trial for 
patients with recurrent pediatric solid tumors   (ClinicalTrials.
gov identifier number NCT01049841). It seeks to build 
on the hypothesis that Akt inhibition by perifosine, in 
conjunction with disruption of the downstream mTOR 
pathway by the rapamycin analog temsirolimus, can have a 
synergistic   anti-tumor effect. Akt targeting with perifosine 
can potentially circumvent the activation of Akt observed 
with mTOR inhibition.109 Furthermore, with the excep-
tion of gastrointestinal side effects, the two drugs have 
non-overlapping toxicities, possibly allowing therapeutic 
use in combination without major toxicity. The MTD of 
temsirolimus as a single agent in children was determined 
to be 150 mg/m2/dose weekly intravenously110 but a dose 
of 75 mg/m2/day has been adopted for Phase II pediatric 
studies.111 The primary objective is to determine the maxi-
mum tolerated doses of perifosine and temsirolimus when 
used in combination. A dosing strategy similar to that used 
for the single agent perifosine study is used for daily oral 
perifosine dosing. Temsirolimus is first escalated from 25 
to 75 mg/m2 IV every 4 weeks with perifosine escalation in 
three cohorts after the final dose of temsirolimus is reached. 
Secondary objectives include measurement of perifosine and 
temsirolimus pharmacokinetics and acquiring preliminary 
data regarding efficacy of the combination. The design of 
further clinical trials using perifosine in pediatrics will likely 
be predicated on the establishment of perifosine MTD in the 
above two studies.
Conclusion
Clinical and laboratory research over the last several 
decades has made considerable progress in understanding 
the biology and improving the therapy of neuroblastoma. 
  However, the long-term survival rate for the high-risk 
patients remains 40%. Therapy aimed at newer therapeutic 
targets should therefore be explored. Akt has a potentially 
pivotal role in mediating RTK signaling in neuroblastoma. 
The Akt   pathway is activated in the majority of neuroblas-
toma and is associated with a poor prognosis. Preclinical 
data suggests that perifosine, an Akt inhibitor, is an effec-
tive therapeutic agent with tolerable toxicity. Ongoing 
Phase I pediatric studies will establish the safety profile for 
this agent in children, but lessons learned from perifosine 
trials in adults suggest that the single agent perifosine is 
unlikely to yield impressive therapeutic results. Based on 
an understanding of its underlying mechanism of action, 
recent preclinical data from neuroblastoma cell lines and 
xenograft studies, and encouraging clinical data from early 
phase studies in adult cancers, perifosine in combination 
with other novel agents or established chemotherapy has 
the potential to add to the increasing armamentarium of 
therapies being developed for the treatment of high-risk 
neuroblastoma.
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